Novel statins: Pharmacological and clinical results

Chiara Bolego; Andrea Poli; Andrea Cignarella; Alberico L. Catapano; Rodolfo Paoletti

doi:10.1023/A:1020656607497

Novel statins: Pharmacological and clinical results

Chiara Bolego, Andrea Poli, Andrea Cignarella, Alberico L. Catapano, Rodolfo Paoletti

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

Original language	English
Pages (from-to)	251-257
Number of pages	7
Journal	Cardiovascular Drugs and Therapy
Volume	16
Issue number	3
DOIs	https://doi.org/10.1023/A:1020656607497
Publication status	Published - 2002

Keywords

HMG-CoA reductase inhibitors
NK-140
Novel statins
Pitavastatin
Pleiotropic effects
Rosuvastatin
ZD 4522

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pharmacology (medical)
Pharmacology

Access to Document

10.1023/A:1020656607497

Fingerprint Dive into the research topics of 'Novel statins: Pharmacological and clinical results'. Together they form a unique fingerprint.

Cite this

@article{304c51d6283c467a9982419a3dbff320,

title = "Novel statins: Pharmacological and clinical results",

abstract = "Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.",

keywords = "HMG-CoA reductase inhibitors, NK-140, Novel statins, Pitavastatin, Pleiotropic effects, Rosuvastatin, ZD 4522",

author = "Chiara Bolego and Andrea Poli and Andrea Cignarella and Catapano, {Alberico L.} and Rodolfo Paoletti",

year = "2002",

doi = "10.1023/A:1020656607497",

language = "English",

volume = "16",

pages = "251--257",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Novel statins

T2 - Pharmacological and clinical results

AU - Bolego, Chiara

AU - Poli, Andrea

AU - Cignarella, Andrea

AU - Catapano, Alberico L.

AU - Paoletti, Rodolfo

PY - 2002

Y1 - 2002

N2 - Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

AB - Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

KW - HMG-CoA reductase inhibitors

KW - NK-140

KW - Novel statins

KW - Pitavastatin

KW - Pleiotropic effects

KW - Rosuvastatin

KW - ZD 4522

UR - http://www.scopus.com/inward/record.url?scp=0036437730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036437730&partnerID=8YFLogxK

U2 - 10.1023/A:1020656607497

DO - 10.1023/A:1020656607497

M3 - Article

C2 - 12374904

AN - SCOPUS:0036437730

VL - 16

SP - 251

EP - 257

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -